Y Intercept Hong Kong Ltd Makes New Investment in Ocugen, Inc. $OCGN

Y Intercept Hong Kong Ltd acquired a new position in Ocugen, Inc. (NASDAQ:OCGN) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 343,557 shares of the company’s stock, valued at approximately $333,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. purchased a new position in Ocugen in the 1st quarter worth $28,000. Vanguard Personalized Indexing Management LLC grew its stake in shares of Ocugen by 48.8% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 29,871 shares of the company’s stock valued at $29,000 after buying an additional 9,791 shares during the last quarter. Baader Bank Aktiengesellschaft grew its stake in shares of Ocugen by 108.8% during the second quarter. Baader Bank Aktiengesellschaft now owns 38,142 shares of the company’s stock valued at $37,000 after buying an additional 19,876 shares during the last quarter. Ethic Inc. purchased a new position in shares of Ocugen in the second quarter worth about $40,000. Finally, Lanham O Dell & Company Inc. bought a new stake in shares of Ocugen in the 1st quarter valued at about $82,000. Institutional investors own 10.27% of the company’s stock.

Ocugen Trading Down 1.4%

OCGN opened at $1.36 on Friday. The business has a 50 day simple moving average of $1.45 and a two-hundred day simple moving average of $1.12. The firm has a market capitalization of $397.53 million, a price-to-earnings ratio of -6.80 and a beta of 4.15. The company has a debt-to-equity ratio of 9.18, a current ratio of 1.83 and a quick ratio of 1.83. Ocugen, Inc. has a one year low of $0.52 and a one year high of $1.90.

Ocugen (NASDAQ:OCGN) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). Ocugen had a negative return on equity of 255.25% and a negative net margin of 1,197.71%.The business had revenue of $1.75 million during the quarter, compared to the consensus estimate of $0.44 million. Analysts predict that Ocugen, Inc. will post -0.2 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on OCGN. Chardan Capital restated a “buy” rating and set a $7.00 target price on shares of Ocugen in a report on Friday, September 19th. Weiss Ratings reissued a “sell (e+)” rating on shares of Ocugen in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Ocugen from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $7.00.

Ocugen Company Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.